(CHESHIRE, Conn.)Alexion Pharmaceuticals Inc. said Tuesday David Keiser will retire as president and chief operating officer at the end of the year. The company said Keiser's responsibilities would...READ MORE
(CHESHIRE, Conn.)Alexion Pharmaceuticals Inc. said Thursday it swung to a third-quarter profit on a surge in sales of its rare blood disorder drug Soliris. Soliris treats paroxysmal nocturnal hemog...READ MORE
(CHESHIRE, Conn. YORK)Drug developer Alexion Pharmaceuticals Inc. said Tuesday its board of directors approved a 2-for-1 stock split. The stock split, which will double the number of shares outstanding,...READ MORE
(CHESHIRE, Conn. YORK)Drug developer Alexion Pharmaceuticals Inc. said Tuesday it expects to report a profit for the next two quarters, and boosted sales guidance for its only product, Soliris.READ MORE
(NEW YORK)A surge in sales of Alexion Pharmaceuticals' rare blood disorder drug Soliris pushed the drug developer to a second-quarter profit, and boosted shares to their highest level in abo...READ MORE
(NEW YORK)Wider international expansion, the confluence of pharmacies and drug suppliers, and a more aggressive generic drug industry will be in focus at the Goldman Sachs annual health care...READ MORE